NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

It was more in the sense of cross-over.

Quote:
Almost 90% of patients have received DCVax-L at some point. -67% received it at randomization, and the rest received DCVax-L after documented disease progression.

Wait and see???

Yes, now there is talk of looking at the documentation for those patients and coming up with a new criteria.

If retrospectively applied equally to both arms that may work in the absence of x-over.

But the patient already crossed years ago.

So, what do you do if you have a SOC patient who progressed, crossed over and received dcvax, and then it turns out the tumor regressed (psPD).

Was that regression due to DCVax on x-over or due to psPD from SOC (we know SOC causes psPD, we don't know if DCVax causes psPD).

How do you handle that? You can't suck the dcvax out of him.

Havoc.